Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis - PubMed
3 hours ago
- #Genitourinary infections
- #SGLT2 inhibitors
- #Heart failure
- SGLT2 inhibitors (SGLT2i) improve outcomes in heart failure (HF) patients but are associated with increased risk of urinary tract infections (UTI) and mycotic genitourinary infections (MGI).
- Genitourinary infections were more frequent in women than men, with pyelonephritis/urosepsis patients being older and having higher comorbidity, while MGI patients were younger with higher diabetes and obesity prevalence.
- Empagliflozin increased the risk of lower UTI and MGI (especially balanitis in men) but not pyelonephritis/urosepsis.
- UTIs were associated with a higher subsequent risk of death, whereas MGIs were not.
- The clinical benefits of SGLT2i remained unchanged regardless of genitourinary infection occurrence.